Compare MIST & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | RANI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 84.6M |
| IPO Year | 2019 | 2021 |
| Metric | MIST | RANI |
|---|---|---|
| Price | $0.36 | $0.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $4.14 | ★ $7.20 |
| AVG Volume (30 Days) | ★ 1.3M | 462.4K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | $210.30 | $317.02 |
| Revenue Next Year | $251.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $0.50 | $0.50 |
| 52 Week High | $3.06 | $1.98 |
| Indicator | MIST | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 24.59 | 38.82 |
| Support Level | N/A | $0.51 |
| Resistance Level | $0.84 | $0.85 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 39.14 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.